Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3924 | Telehealth Consultation Wiki | 1.00 |
| drug2420 | Molgramostim nebuliser solution Wiki | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
To assess the safety and tolerability of inhaled molgramostim nebuliser solution in patients with COVID-19 pneumonia.
Description: Need for mechanical ventilation within 15 days after randomization
Measure: Mechanical ventilation Time: During 15 daysDescription: Not hospitalized, no limitations on activities Not hospitalized, limitation on activities; Hospitalized, not requiring supplemental oxygen; Hospitalized, requiring supplemental oxygen; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, on invasive mechanical ventilation or ECMO; Death.
Measure: Clinical status of subject at day 15 and day 29 (on a 7-point ordinal scale): Time: At day 15 and day 29Description: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] will be measured at day 0 (day before first dose), day 1-9, and day 15
Measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Time: At day 0 (day before first dose), day 1-9, and day 15Description: Need for oxygen supply (l/min) to reach peripheral oxygen saturation of 98%
Measure: Oxygen supply Time: At day 0, day 1-7, day 8-9 (24 hours/48 hours post dose) and day 15Description: Clinical parameter (4 times daily): temperature (°C degree)
Measure: Clinical parameter: temperature Time: Max. 48 hours before day 0, at day 0, day 1-7, day 8-9 and day 15Description: Clinical parameter (4 times daily): blood pressure (mmHg)
Measure: Clinical parameter: blood pressure Time: Max. 48 hours before day 0, at day 0, day 1-7, day 8-9 and day 15Description: Clinical parameter (4 times daily): hear beat (beats per minute)
Measure: Clinical parameter: heart beat Time: Max. 48 hours before day 0, at day 0, day 1-7, day 8-9 and day 15Description: Clinical parameter (4 times daily): respiratory rate (breaths per minute)
Measure: Clinical parameter: respiratory rate Time: Max. 48 hours before day 0, at day 0, day 1-7, day 8-9 and day 15Description: Presence of Severe acute respiratory syndrome coronavirus 2 nucleic acid by PCR test in swabs or tracheal aspirates/bronchoalveolar lavage
Measure: Severe acute respiratory syndrome coronavirus 2 polymerase chain reaction (PCR) Time: Max. 48 hours before day 0 and at day 8-9Description: C-reactive protein test measures the amount of C-reactive protein in blood (mg/L)
Measure: Laboratory: C-reactive protein test Time: At day 0, day 1-7, day 8-9 and day 15Description: Ferritin test measures the amount of ferritin in the blood (ng/ml)
Measure: Laboratory: ferritin Time: At day 0, day 1-7, day 8-9 and day 15Description: Interleukin-6 test (IL-6) measures the amount of IL-6 in the blood (pg/ml)
Measure: Laboratory: Interleukin-6 Time: At day 0, day 1-7, day 8-9 and day 15Description: Procalcitonin (PCT) test measures the amount of PCT in the blood in (μg/l)
Measure: Laboratory: procalcitonin Time: At day 0, day 1-7, day 8-9 and day 15Description: Occurrence of secondary bacterial pneumonia
Measure: Bacterial pneumonia Time: At day 0, day 1-7, day 8-9 and day 15Description: Days on vaso-active drugs in a 29-day period
Measure: Vaso-active drugs Time: At day 29Description: All-cause mortality
Measure: Mortality Time: At day 29Description: GM-CSF levels in serum
Measure: GM-CSF Time: At day 0 and day 1-7Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports